FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. - Brodowicz, T.; Ciuleanu, T. E.; Radosavljevic, D.; Shacham-Shmueli, E.; Vrbanec, D.; Plate, S.; Mrsic-Krmpotic, Z.; Dank, M.; Purkalne, G.; Messinger, D.; Zielinski, C. C. (Annals of Oncology, 2013)